Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

EarningsVK2735Positive

AI Analysis

Summary

Viking Therapeutics reported Q2 2026 results and announced full enrollment of Phase 3 VANQUISH 1 & 2 trials for subcutaneous VK2735 in obesity, with maintenance dosing data expected in 3Q26 and oral Phase 3 trial initiation anticipated in 4Q26.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Q2 2026 financial results and corporate update; Phase 3 VANQUISH 1 & 2 trials fully enrolled; maintenance dosing data expected 3Q26; oral Phase 3 trial initiation expected 4Q26

Importance:7/10

Sentiment:

0.70

Phase 3 enrollment completeVK2735 obesitySubcutaneous formulationOral formulation in developmentMaintenance dosing data pendingEarnings report

Related Companies

$VKTX

Read the original article

Published by PR Newswire Biotech on July 29, 2026 8:05 PM

Read Original